Naohiro Okano

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 334 citations

Medicine, Oncology, Chemotherapy +7

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno, Masafumi Ikeda, Chigusa Morizane et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 332 citations

Medicine, Oncology, Chemotherapy +5

First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors

Naohiro Okano, Daisuke Naruge, Kirio Kawai et al. · Investigational New Drugs · 2020 · 206 citations

Medicine, Oncology, Pharmacology +5

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi et al. · European Journal of Cancer · 2022 · 85 citations · Full text

Medicine, Oncology, Pharmacology +12

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial

Akihiro Ohba, Chigusa Morizane, Makoto Ueno et al. · Future Oncology · 2022 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17